Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

HealthGen Achieves Exclusive Greater China License for Influenza Antiviral Drug TG-1000, Continuing its Momentum in High-Quality R&D Pipeline Layout

Published Time:

2023-04-06

Recently, Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Joincare") and TaiGen Biotech Co., Ltd. and TaiGen Pharmaceutical R&D (Beijing) Co., Ltd. (hereinafter referred to as "TaiGen") signed an exclusive license agreement for the latter's influenza antiviral drug TG-1000 in Greater China.

According to publicly available information, TaiGen is a biotechnology company focusing on the research and development of anti-infective drugs. TaiGen's innovative drug TG-1000 is a novel mechanism of action—Cap-dependent endonuclease inhibitor, which acts on the cap snatching mechanism necessary for viral replication. It can block viral endonucleases in cells, effectively blocking viral replication and transmission, and is expected to overcome the problem of drug-resistant virus strains and has a wider effective treatment period. Currently, the new drug TG-1000 has completed Phase II clinical trials in 2022.

According to the World Health Organization, influenza outbreaks cause 3 to 5 million people to become seriously ill each year. Although influenza outbreaks are caused by minor seasonal changes in influenza virus genes, a more worrying change is that these viruses form new genes, transforming into new viruses that no one is immune to. In addition, newly mutated viruses are prone to developing resistance to antiviral drugs, and the development of innovative influenza drugs is indeed urgently needed.

In this regard, Mr. Zhu Baoguo, Chairman of Joincare, said: "TaiGen has rich experience in the research and development of innovative drugs for anti-infective diseases. We have seen its performance in treating influenza, reducing viral load in the body, and pharmacokinetics in the preclinical and Phase I and II clinical data of TG-1000. We are optimistic about the future potential of TG-1000. This cooperation will not only expand Joincare's R&D pipeline but also is expected to bring more treatment options to patients."

Joincare Pharmaceutical Group was founded in 1992. After years of steady operation and rapid development, it has become an innovative and research-oriented comprehensive pharmaceutical group. It owns two large listed companies, Joincare and Lizhu Pharmaceutical, and more than 20 major holding subsidiaries. Joincare has always adhered to technological innovation as its strategic foundation and aims to drive innovation drugs and high-barrier complex preparation technology platforms. It has made rich pipeline layouts in areas with significant clinical needs, such as respiratory, digestive tract, assisted reproduction, mental, and tumors, forming a rich and diverse product matrix and R&D drug pipeline. According to Frost & Sullivan data, Joincare was the sixth largest comprehensive pharmaceutical company listed in China in 2021 in terms of revenue. In addition, according to the Pharmaceutical Intelligence Listed Enterprise Product R&D Details Database statistics, Joincare and its holding subsidiary Lizhu Group ranked seventh and ninth in R&D investment in the domestic pharmaceutical industry in 2021, respectively, with a high change ranking among the top four, which is at a high level in the same industry.

In recent years, Joincare has launched several high-quality inhalation products, gradually breaking through the development bottlenecks in the sub-industry and becoming the first enterprise in the respiratory drug field to break the international market monopoly. Currently, 7 varieties and 11 specifications of inhalation products have been launched, and more than 30 varieties of products are under research, successfully covering all categories of asthma and COPD inhalation treatment drugs in existing and under-research varieties.

While internal driving force continues to strengthen, Joincare Group is also actively exploring cutting-edge technologies and development opportunities at home and abroad, increasing the intensity of introducing high-quality pipelines. It has carried out strategic cooperation with scientific research institutions and innovative companies such as the Chinese Academy of Sciences and Tencent Quantum Laboratory, focusing on clinical value and laying out R&D projects with high short-term certainty and cutting-edge technologies with long-term growth potential, such as AI innovative drug molecular design, PROTAC, synthetic biology, gene editing, and cell therapy, to expand its own product matrix and R&D pipeline. At the end of 2022, Joincare, together with its holding subsidiary Lizhu Group, invested 1 billion yuan to establish an industrial investment entity for strategic investment in high-quality major health projects, accelerating the construction of a diversified R&D innovation project incubation and introduction platform. Recently, Joincare's holding subsidiary Lizhu Group also announced the introduction of an innovative drug, a potassium-competitive acid blocker, for the treatment of digestive diseases, further expanding the group's digestive tract pipeline. With independent R&D as the foundation and external introduction as the accelerator, Joincare's innovation journey has entered a new stage.

"We are very pleased to sign this cooperation agreement with Joincare!" Mr. Huang Guolong, Chairman and CEO of TaiGen, said, "TG-1000 is a new drug independently developed by TaiGen, which can effectively inhibit influenza A and B viruses. We have great expectations and confidence in the development of TG-1000. Joincare's professional technology in raw materials and preparation development platforms occupies a superior strategic position in the domestic pharmaceutical industry. TaiGen believes that with Joincare's development, TG-1000 can create excellent prospects in China." According to previously reported animal experiment data, TG-1000 has higher safety and better blood drug concentration and is not easily affected by influenza virus mutations to produce drug resistance. If successfully launched in the future, it may seize the vast domestic market for anti-influenza virus drugs.

 

 

Source: Blue Whale